Inclusion Criteria:

1. Provision of signed written informed consent;

2. Male or female subjects, aged at least 18 years;

3. Subjects with liver metastases (3 to 10 cm diameter) from colorectal and ovarian
cancers;

4. failure of standard cancer therapy;

5. ECOG performance status of 0 to 1 at study entry and an estimated life expectancy of
at least 3 months;

6. Adequate hematological function, defined by absolute neutrophil count (ANC) ≥ 1.5 x
.109 / L, platelet count ≥ 100 x .109 / L, and hemoglobin concentration ≥ 9 g / dL;

7. As subjects with documented liver metastases are treated in this trial, liver
function test values are accepted as followed: up to the upper limit of CTC Grade 2.
This includes total bilirubin level ≤3 times the upper limit of normal (ULN), and
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤5 x ULN.

8. Adequate renal function defined by serum creatinine ≤1.5 x ULN or a creatinine
clearance of ≥50 mL/min calculated by Cockroft-Gault;

9. Effective contraception (e.g., double barrier method) for both male and female
subjects if the risk of conception exists. These subjects must be willing to avoid
pregnancy during the study (screening to EOS) as well as for at least 3 months after
the last dosing.

Exclusion Criteria:

1. Any systemic cancer treatment within 30 days before treatment with EMD 525797;

2. Thrombolytics or oral or parenteral anticoagulants (except to maintain patency of pre
existing, permanent indwelling IV catheters) within 10 days prior to study start and
during treatment;

3. Radiotherapy, chemotherapy, surgery, or any investigational drug in the 30 days
before the start of treatment in this study, and/or diagnostic biopsies within 2
weeks before the start of treatment in this study;

4. Previous treatment with anti integrin therapy or anti angiogenic therapy within the
last 6 months;

5. Confirmed or clinically suspected brain metastases;

6. Known hypersensitivity reactions to the study medication;

7. History of allergic reactions to other monoclonal antibody (mAb) therapy;

8. Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic >100 mmHg);

9. Current history of chronic daily aspirin therapy (ASS at doses ≤ 150 mg is
permitted), bleeding disorders, and/or history of thromboembolic events;

10. Severe peripheral vascular disease or ulceration;

11. Unstable angina pectoris, or myocardial infarction within 6 months before start of
study treatment, clinical significant abnormal ECG at screening;

12. In women of childbearing potential, pregnancy (absence to be confirmed by beta human
chorionic gonadotropin [β HCG] test, unless a subject has previously undergone
hysterectomy or bilateral ovariectomy), or lactation period;

13. Known alcohol or drug abuse;

14. Participation in another clinical trial within the past 30 days before start of study
treatment;

15. All other significant diseases which, in the opinion of the PI, might impair the
patient's tolerance of study treatment;

16. Dementia, altered mental status, or any psychiatric condition that would prohibit the
understanding or rendering of informed consent;

17. Legal incapacity or limited legal capacity (not applicable only in rare cases);

18. Known HIV infection and/or active hepatitis B or C virus infections;

19. Ongoing uncontrolled infections;

20. Contraindications to MRI